Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (non-LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2003
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Well performed study with deviations: no information on age and housing conditions of animals; details on patch material, nature and degree of toxicity, grading system not mentioned
Cross-referenceopen allclose all
Reason / purpose for cross-reference:
reference to same study
Reason / purpose for cross-reference:
reference to other study

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
2003

Materials and methods

Principles of method if other than guideline:
The cumulative contact enhancement test (Tsuchiya et al. 1985)
GLP compliance:
no
Type of study:
patch test
Justification for non-LLNA method:
Litterature data allow us to classify delta-3-carene as skin sensitiser and the method applied is a non-LLNA method.

Test material

Constituent 1
Chemical structure
Reference substance name:
3,7,7-trimethylbicyclo[4.1.0]hept-3-ene
EC Number:
236-719-3
EC Name:
3,7,7-trimethylbicyclo[4.1.0]hept-3-ene
Cas Number:
13466-78-9
Molecular formula:
C10H16
IUPAC Name:
3,7,7-trimethylbicyclo[4.1.0]hept-3-ene
Test material form:
liquid

In vivo test system

Test animals

Species:
guinea pig
Strain:
Dunkin-Hartley
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Weight at study initiation: 250-300 g

Study design: in vivo (non-LLNA)

Inductionopen allclose all
Route:
epicutaneous, occlusive
Vehicle:
olive oil
Concentration / amount:
0%
Day(s)/duration:
10
Route:
epicutaneous, occlusive
Vehicle:
olive oil
Concentration / amount:
1%
Day(s)/duration:
10
Route:
epicutaneous, occlusive
Vehicle:
olive oil
Concentration / amount:
3%
Day(s)/duration:
10
Route:
epicutaneous, occlusive
Vehicle:
olive oil
Concentration / amount:
10%
Day(s)/duration:
10
Challengeopen allclose all
No.:
#1
Route:
epicutaneous, occlusive
Vehicle:
arachis oil
Concentration / amount:
0%
No.:
#2
Route:
epicutaneous, occlusive
Vehicle:
arachis oil
Concentration / amount:
1%
No.:
#3
Route:
epicutaneous, occlusive
Vehicle:
arachis oil
Concentration / amount:
3%
No.:
#4
Route:
epicutaneous, occlusive
Vehicle:
arachis oil
Remarks:
and arachis oil
Concentration / amount:
10%
No. of animals per dose:
12 or 10
Details on study design:
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: Four
- Exposure period: 24 hours
- Control group: Vehicle only, olive oil
- Site: Scapular region
- Duration: 10 days with an intradermal injection of Freuds complete adjuvant at the third event followed by an open skin test on day 21.
- Concentrations: 50%

B. CHALLENGE EXPOSURE
- Control group: Vehicle only, arachis oil
- Site: Shaven Flanks
- Concentrations: 10, 3 and 1%


Challenge controls:
10 challenge controls
Positive control substance(s):
no

Results and discussion

In vivo (non-LLNA)

Resultsopen allclose all
Key result
Reading:
1st reading
Hours after challenge:
0
Group:
test chemical
Dose level:
1%
No. with + reactions:
8
Total no. in group:
12
Clinical observations:
Minimum criterion for positive reaction: erythema
Key result
Reading:
1st reading
Hours after challenge:
0
Group:
test chemical
Dose level:
3%
No. with + reactions:
8
Total no. in group:
12
Clinical observations:
Minimum criterion for positive reaction: erythema
Key result
Reading:
1st reading
Hours after challenge:
0
Group:
test chemical
Dose level:
10%
No. with + reactions:
8
Total no. in group:
12
Clinical observations:
Minimum criterion for positive reaction: erythema
Key result
Reading:
2nd reading
Hours after challenge:
0
Group:
test chemical
Dose level:
1%
No. with + reactions:
7
Total no. in group:
10
Clinical observations:
Minimum criterion for positive reaction: erythema
Key result
Reading:
2nd reading
Hours after challenge:
0
Group:
test chemical
Dose level:
3%
No. with + reactions:
7
Total no. in group:
10
Clinical observations:
Minimum criterion for positive reaction: erythema
Key result
Reading:
2nd reading
Hours after challenge:
0
Group:
test chemical
Dose level:
10%
No. with + reactions:
7
Total no. in group:
10
Clinical observations:
Minimum criterion for positive reaction: erythema
Reading:
other: not measured/tested
Hours after challenge:
0
Group:
negative control
Dose level:
None
No. with + reactions:
0
Total no. in group:
0
Clinical observations:
None
Remarks on result:
not measured/tested
Reading:
other: not measured/tested
Hours after challenge:
0
Group:
positive control
Dose level:
None
No. with + reactions:
0
Total no. in group:
0
Clinical observations:
None
Remarks on result:
not measured/tested

Any other information on results incl. tables

None

Applicant's summary and conclusion

Interpretation of results:
Category 1B (indication of skin sensitising potential) based on GHS criteria
Remarks:
Migrated information
Conclusions:
delta-3-Carene was found to be a skin sensitiser.
Executive summary:

delta-3 -Carene was tested for skin sensitisation in female Dunkin-Hartley guinea pigs. Groups of guinea pigs (10 or 12/group) received four occluded dermal exposure for 24 hours in scapular region of 50% delta-3-carene followed by challenge dose on the shaven flanks with 10, 3, 1% and vehicle.

 

In the first set of experiments 8 out of 12 and in second, 7 out of 10 animals showed presence of erythema which was considered as positive reaction.

Therefore, delta-3-carene was found to be a skin sensitiser.